ESR1 mutations: Pièce de résistance  by Button, Berry & Park, Ben Ho
Genes & Diseases (2016) 3, 124e129HOSTED BY Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http: / /ees.elsevier .com/gendis/default .aspREVIEW ARTICLEESR1 mutations: Pie`ce de re´sistance
Berry Button a,c, Ben Ho Park a,b,*,da The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine,
Baltimore, MD, United States
b Department of Chemical and Biomolecular Engineering, The Whiting School of Engineering, The Johns
Hopkins University, Baltimore, MD, United StatesReceived 7 February 2016; accepted 29 March 2016
Available online 19 April 2016KEYWORDS
Breast cancer;
Circulating tumor
DNA;
ESR1;
Estrogen receptor;
Mutation;
Plasma* Corresponding author.
E-mail addresses: bbutton1@jhm
jhmi.edu (B.H. Park).
Peer review under responsibil
University.
c 1650 Orleans Street, CRBI, Room
United States.
d 1650 Orleans Street, CRBI, Room
United States.
http://dx.doi.org/10.1016/j.gendis.2
2352-3042/Copyright ª 2016, Chongqi
CC BY-NC-ND license (http://creativeAbstract Estrogen and estrogen receptor-alpha (ER) signaling are important factors in the
pathogenesis and treatment of ER-positive breast cancers. Therefore targeted therapies
against ER, known as endocrine therapies, are widely used in the treatment of ER-positive
breast cancers. While these therapies have shown great success, de novo and acquired resis-
tance are common. The approach to the problem of endocrine therapy resistance is two-
fold: identify the mechanisms of resistance and develop alternative treatments to overcome
these mechanisms. This review focuses on the progress and integration of these two aspects
of resolving endocrine therapy resistance in ER-positive breast cancer patients.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
The estrogen receptor-alpha (ER), encoded by the gene
ESR1, is a nuclear steroid hormone receptor which acts as a
transcription factor to regulate proliferation andi.edu (B. Button), bpark2@
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ng Medical University. Production
commons.org/licenses/by-nc-nd/differentiation of cells in which it is expressed. Estrogen
signaling via ER plays a major role in elements of the female
reproductive cycle such as ovulation and mammary gland
development, and ER is highly expressed in corresponding
tissues such as the ovaries and breasts and has been linked
to carcinogenesis in those tissues. Despite the under-
standing that all cancers are genetic diseases, genetic al-
terations in ESR1 are rarely found in primary breast tumors.
This led to the notion that ESR1 gene alterations are not
involved with breast carcinogenesis despite the importance
of ER signaling for therapeutic intervention in the majority
of breast cancer patients. However, more contemporary
studies have suggested that mutations in ESR1 are now
known to be mediators of resistance to endocrine thera-
pies. Thus, although ESR1 mutations are not likely to be
involved with the development of breast cancers, theand hosting by Elsevier B.V. This is an open access article under the
4.0/).
ESR1 mutations 125recognition of ESR1 mutations in metastatic disease may
lead to newer therapies that can overcome resistance for
therapeutic benefit.
ER signaling
In “classical” ER signaling, binding of the ligand estrogen to
ER induces dimerization and activation of the receptor
complex (Fig. 1). In addition to a ligand-binding domain
(LBD), ER contains a DNA-binding domain which recognizes
estrogen response elements (EREs) in the genome and a
transactivation domain which induces changes in tran-
scriptional activity at EREs upon ligand-dependent receptor
activation and DNA binding. A number of co-activators and
co-repressors have been shown to form complexes with ER
in order to modulate its activitydthe balance of co-
activator/co-repressor expression in different tissues and
under different cellular conditions is thought to be a major
factor in ER functionality and even tissue-specific responses
to endocrine therapies targeting ER signaling in the cancer
setting.1,2
In “non-classical” ER signaling, ER can alternatively
interact with non-ERE genomic loci and/or become acti-
vated under ligand-independent conditions. Transcription
factors such as AP-1, Sp1, and NF-kB can interact with ER,
conferring the ability to recognize non-traditional response
elements for transcriptional activation.3 Additionally, post-
translational modifications to ER that occur downstream of
certain receptor tyrosine kinases and G-protein coupled
receptors can induce ligand-independent ER signaling. This
includes modulating three well-characterized phosphory-
lation sites of ER which can be acted upon by importantEstrogen
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Fig. 1 Estrogen receptor-alpha (ER) signaling and related targ
genomic responses which contribute to the behavior of the cell.
works, such as mTOR and MAPK, can mitigate tumorigenic propertadditional kinases such as MAP kinase, Akt, protein kinase
A, and HER2, respectively.4,5 The integration of these well-
described pathways with ER activity has profound implica-
tions for normal ER function, as well as its role in cancer
and resistance to endocrine therapies. For example, phos-
phorylation of ER by HER2 and other kinases may circum-
vent estrogen-dependence of ER activation, contributing to
resistance to anti-estrogen endocrine therapies.6 ER is also
capable of non-genomic signaling activities, and has been
described to have non-nuclear interactions via interactions
with a number of important cellular signaling factors, most
notably proteins within the MAP kinase signaling pathway.7ER in breast cancer pathology
The complex but compelling role of ER in breast cancer has
long been recognized. ER is expressed in approximately 70%
of breast cancers, usually along with other markers that are
often found in luminal breast epithelial cells; ER
expressing (ERþ) breast cancers have thus been deemed
luminal type. This group has been further divided into
luminal A and luminal B subtypes, distinguished by signifi-
cant expression of genes such as HER2 or Ki67 in luminal B
tumors. Luminal A type breast cancer is generally associ-
ated with a better prognosis than the other breast cancer
subtypes due to a combination of factors: it tends to be
more differentiated and less aggressive than other sub-
types, the rate of recurrence is lower and slower, and there
are ever-increasing numbers of targeted therapies against
ER and ER-related signaling being developed and approved
for this disease subtype. Generally speaking, most but notmily
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receptor expression.Endocrine therapies
The difficult-to-tolerate side effects of systemic chemo-
therapy have led to efforts to identify and develop targeted
cancer therapies wherever possible. The crucial role of ER
in luminal breast cancer has led to wide use of three broad
classes of endocrine therapies against ER signaling in the
breast.
A class of drugs deemed selective estrogen receptor
modulators (SERMs) confers a change in ER activity based on
conformational change and/or co-repressor binding. All
SERMs are partial ER agonists, exhibiting anti-proliferative
activity in breast tissue but estrogenic activity in other
peripheral tissues such as endometrium and bone,
depending on the particular SERM.8 In randomized clinical
trials, the first-generation SERM tamoxifen has performed
well and subsequently been approved for prevention of
breast cancer in high-risk patients, as an adjuvant treat-
ment for early disease in pre- and postmenopausal women,
and as first-line therapy in metastatic breast cancer. How-
ever, tamoxifen use is associated with increased risk of
endometrial cancer and thromboembolic events. Raloxi-
fene, a second-generation SERM, is also used for prevention
of breast cancer and has shown a reduction of side effects,
notably endometrial cancer, when compared with tamox-
ifen in breast cancer clinical trials (although raloxifene’s
primary use is in the treatment of osteoporosis).8 Impor-
tantly, raloxifene is not used for the treatment of breast
cancer. Several third-generation SERMs are currently under
investigation in clinical trials, including toremifene, which
has been used successfully in the early adjuvant and met-
astatic settings but has a safety profile similar to that of
tamoxifen and bazedoxifene.
Selective estrogen receptor down-regulators (SERDs)
such as fulvestrant reduce ER activity and induce its pro-
teasomal degradation. Unlike SERMs, fulvestrant exhibits
full antagonistic activity of ER in all tissues. Fulvestrant is
currently a second-line endocrine therapy given to post-
menopausal ERþ breast cancer patients with advanced
disease, and promising results from recent clinical trials
indicate that it may be used in other settings as well, such
as first-line therapy and in premenopausal patients.9,10 In
addition to fulvestrant, two candidate SERDs with improved
bioavailability are being evaluated in Phase I clinical tri-
als.11,12 These latter two SERDs have the significant
advantage of oral formulations, compared to fulvestrant
which requires monthly gluteal intramuscular injections.
Aromatase inhibitors (AIs) greatly reduce production of
estrogen in the body, thus removing the main source of ER
activation. This class includes the steroidal AI exemestane,
as well as the non-steroidal AIs letrozole and anastrozole.
AIs can only be used in post-menopausal women or pre-
menopausal women who no longer have ovarian production
of estrogen, either through surgical removal of the ovaries
or from luteinizing releasing hormone agonists, such as
goserelin. This is because ovarian production of estrogen
does not rely upon aromatase, an enzyme that is a cyto-
chrome P450 family member. In the post-menopausal state,aromatase is the major if not exclusive source of estrogen
production. For post-menopausal breast cancer patients,
AIs have been proven to be superior to tamoxifen in the
majority of trials. Thus, these drugs constitute the standard
first-line adjuvant and metastatic endocrine therapies for
post-menopausal ERþ/HER2 breast cancer patients.
Endocrine therapy resistance
Although all three drug classes are used effectively in pa-
tients with ERþ/HER2 breast cancer, resistance to these
therapies has become a major hurdle.6 Almost half of ERþ/
HER2 patients do not respond to endocrine therapies,
termed primary or de novo resistance. In addition, the
majority of metastatic patients who initially respond to
endocrine therapies will eventually progress or relapse,
termed secondary or acquired resistance. The mechanisms
for resistance have not been fully elucidated, but depend
on estrogen-independent survival and proliferation of the
tumor cells.
Combination therapies
Due to challenges with resistance to endocrine therapies,
additional options for the treatment of ERþ/HER2 breast
cancer have emerged and others are under investigation. As
in other cancers, it is thought that combination therapies,
by halting multiple signaling pathways at once, will prevent
ERþ/HER2 tumors from evolving compensatory mecha-
nisms to bypass ER signaling. Therefore, a number of non-
endocrine targeted agents have been tested in combination
with endocrine therapies and more studies are underway.
Several promising agents have been identified and are now
approved therapies for ERþ/HER2 disease.
Complex crosstalk between PI3 kinase/mTOR and ER
signaling pathways suggests that targeting of both pathways
could be detrimental to ERþ tumor growth.13 For this
reason, the BOLERO trials tested the hypothesis that the
mTOR inhibitor everolimus in combination with current
endocrine therapies could improve outcomes for metastatic
ERþ patients with endocrine therapy resistant disease.
Improved outcomes demonstrated by the BOLERO-2 trial
have resulted in approval of the combination of everolimus
and exemestane for clinical use in advanced ERþ breast
cancers.14 Further BOLERO studies will test everolimus in
combination with other endocrine agents such as letrozole
and in additional breast cancer settings such as premeno-
pausal and/or endocrine-naı¨ve patients.15
Another hypothesis posits that cell cycle arrest could
enhance endocrine therapy.16 The CDK 4/6 inhibitors pal-
bociclib and ribociclib are therefore interesting candidates
for combination therapy, and numerous trials have been
initiated with these agents. Early results of the PALOMA
trials have demonstrated improved outcomes with palbo-
ciclib in combination with certain endocrine therapies
including letrozole and fulvestrant and further studies are
underway.15,17 This has led to the FDA approval of letrozole
and palbociclib for first-line therapy in metastatic ERþ/
HER2 breast cancer patients.
Finally, HDAC inhibitors such as entinostat may deregu-
late ESR1 transcription sufficiently to overcome endocrine
Table 1 Identification of ESR1 variants in hormone-resis-
tant advanced breast cancer.
Study ER variant
types detected
n Variant
rate
Li et al 2013 Amplification,
fusion, mutation
7 57%
Merenbakh-Lamin
et al 2013
Mutation 13 38%
Robinson et al 2013 Mutation 11 55%
Toy et al 2013 Mutation 80 18%
Jeselsohn et al 2014 Mutation 76 12%
ESR1 mutations 127resistance. The ENCORE 301 study demonstrated improved
outcomes with entinostat and exemestane combination
therapy and confirmatory trials are underway.14
On the other hand, studies of several additional classes
and combinations of targeted agents have met with limited
success in ERþ breast cancers. Anti-angiogenic agents,
multi-target kinase inhibitors, EGFR inhibitors, and poly-
endocrine therapy did not significantly improve outcomes in
their respective trials but may benefit from the identifica-
tion of biomarkers that can select for patient populations
most likely to benefit from these therapies either singly or
in combination.
Amplification of ESR1
Although ER is highly expressed in a large proportion of
breast cancers, it appears that this is largely not a product
of ESR1 amplification. This issue was controversial after a
2007 fluorescent in situ hybridization study indicated that
significant ESR1 amplification was present in over 20% of
breast cancers.18 Later studies failed to replicate this rate
of amplification and it was eventually suggested that
accumulation of ESR1 transcripts in the nucleus may have
been responsible for the perceived amplification and its
association with strongly ERþ breast cancer.19 However,
another recent study found that amplification of ESR1
occurred in MCF7 cells (a widely used breast cancer cell
line) after long-term estrogen deprivation, which may
model the paradoxical clinical phenomenon in which long-Fig. 2 Schematic diagram of estrogen receptor-alpha (ER). The
domains for DNA binding, transactivation functions 1 and 2, and
variation of the ligand binding domain at residues 536, 537, and
domain, which is known to regulate ligand binding and recruitment
basis for ligand-dependent activation of the ER.term endocrine therapy in a small subset of patients leads
to estradiol hypersensitivity.20 In this group, estradiol may
be useful as a breast cancer therapy which causes apoptosis
in hypersensitive cells, thus stabilizing the tumor.
ER variants
As an important clinical target in breast cancer, ER seems
to be a clear candidate to carry mutations that drive
endocrine therapy resistance. Early in vitro mutagenesis
studies of ESR1 identified dominant-negative and ligand-
independent forms of the ER protein21 and in vivo and
clinical studies identified acquired mutations which
mediate the effects of tamoxifen,22,23 but large clinical
surveys have shown, somewhat surprisingly, that ER vari-
ants are rare in primary breast cancer.24 However, it has
been suggested that ER variants play a role in advanced
breast cancer25 and indeed, recent studies have identified
rearrangements and recurrent somatic mutations of ESR1 in
metastatic hormone-resistant disease.20,26e29 Each of these
studies has detected a significant rate of ESR1 mutation or
variation (Table 1). In various forms, the authors of these
studies suggest that the low-estrogen conditions achieved
by the endocrine therapies favor somatic variation of ESR1
in order for tumor cells to adapt and thrive.
Notably, there appears to be a mutational hot spot re-
gion in the ER LBD at residues 536e538, which includes a
tyrosine phosphorylation site at residue 537 (Fig. 2).
Mutagenesis studies have identified the critical role of
these amino acids in regulation of ER activity.30,31 A number
of different substitutions within this hot spot have been
shown to confer constitutive ligand-independent activation
of ER, suggesting that these naturally-occurring mutations
likely play a role in acquired resistance to endocrine
therapies.20,26e29 These residues lie within helix 12 of the
LBD, which is responsible for closing the LBD pocket upon
ligand binding and creating a surface with which co-
regulators can interact. As shown in structural modeling
of one particular LBD mutation, D538G, changes to helix 12
can result in a conformational change that, even in the
absence of ligand, mimics the ligand-bound form of ER.29
This not only precludes binding of ligands such as estra-
diol, tamoxifen, and fulvestrant but also allows ligand-
independent co-activator recruitment. Finally, this ligand-ESR1 gene encodes the nuclear receptor protein ER, containing
ligand binding. The most common ESR1 mutations result in
538. These residues are part of Helix 12 of the ligand binding
of co-repressors and co-activators, therefore constituting the
128 B. Button, B.H. Parkindependent ER has constitutive transcriptional activity at
EREs and may contribute to enhanced cell proliferation and
migration.29
A study of patient-derived breast cancer xenografts,
which also detected LBD hot spot mutations, noted one
chromosomal translocation between the coding regions of
ESR1 and YAP1 leading to an in-frame, expressed fusion
protein.20 Much like two previously identified naturally-
occurring ER fusion proteins, the N-terminus of ER con-
taining the DNA-binding domain and AF1 transactivation
domain was preserved but the C-terminus was replaced by
that of YAP1dthus losing the LBD and AF2 transactivation
domain of ER. Although the physical genetic properties are
quite different from the LBD mutations discussed above,
this fusion protein similarly gained ligand-independence
while preserving DNA-binding and transactivation func-
tion. However, while LBD point mutations will alter ligand
affinities and contribute to resistance to particular endo-
crine therapies, complete loss of the LBD as in these fusion
proteins leads to an “intrinsic and universal endocrine-
therapy resistance” which will need to be addressed with
different clinical strategies.20 While clearly occurring at a
low frequency, the recurrence of this type of fusion protein
across three studies indicates that the effect is robust and
almost certainly drives endocrine therapy resistance in this
small subset of patients.
It is likely that ER variants can be categorized according
to the type of endocrine therapy that they resist: SERM and
SERD resistance depends upon changes to the protein’s
interaction with the drug, while AI resistance depends upon
estrogen-independent activity of the receptor or of the cell
itself. Since ER varies widely in its affinity for various li-
gands, it may be that each individual LBD mutation will
confer a different effect on each individual recep-
toreligand interaction, which will have profound effects on
endocrine therapy decisions for patients with these
mutations.
Finally, it cannot be ignored that these mutations were
identified only after the recent practice of obtaining met-
astatic biopsies for sequencing. Although some studies have
suggested that these LDB mutations are in primary tu-
mors,28 most studies have not validated these results. We
now understand, based on these studies and others, that a
single biopsy from the primary tumor is usually not repre-
sentative of a patient’s heterogeneous and ever-evolving
tumor cell population. For example, some of the afore-
mentioned studies of ESR1 mutations identified mutations
in one site of disease but not other metastatic sites within
the same patient.28,29 In this respect, we have demon-
strated that a “liquid biopsy” technique, which is repre-
sentative of all disease sites in the body including
micrometastatic disease, can detect low-frequency muta-
tions including those in ESR1.32 We speculate that in the
future this will provide additional information to make the
best treatment decisions. Thus, the lesson learned from
cancer genome sequencing studies over the past decade is
that profiling a patient’s primary tumor may be inadequate
to truly understand the molecular evolution of metastatic
disease. In this regard, liquid biopsies may allow a more
comprehensive profiling of a patient’s total disease burden,
and for ER positive disease, further characterization of
ESR1 variants. This, along with ongoing drug development,has brought about a positive outlook for ERþ/HER2 breast
cancer patients.
Conclusions
The characterization of clinically relevant ESR1 variants
and their sensitivity to various endocrine therapies will be
crucial for optimal treatment for this subset of ERþ breast
cancers. The advent of molecular profiling and precision
medicine brings the opportunity to account for these ESR1
variants and treat patients accordingly. While new thera-
pies may be needed for certain variants, higher doses of
already approved therapies may afford near term benefit, a
testable hypothesis for clinical trials.29 In addition, the
continued development of newer SERMs and SERDs, along
with novel therapeutic combinations, may allow for
improved outcomes for patients with metastatic ERþ/
HER2 disease.
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